The acquisition is subject to regulatory approval and to the agreement of shareholders to sell at least 80 percent of Advanced Accelerator Applications’ outstanding ordinary shares to Novartis. Under the terms of the deal, Novartis has offered to pay $41 per ordinary share and $82 per American depositary share. The company reported sales of $48.5 billion last year and has about 121,000 employees. Novartis said in a news release that the transaction would strengthen the company’s stable of cancer treatments “with both near-term product launches as well as a new technology platform with potential applications across a number of oncology early development programs.” Lutathera is under review by the authorities in the United States. Its products include Lutathera, which recently received approval from regulators in Europe to treat certain types of tumors. It had sales of 109 million euros, or about $126.5 million, in 2016. Advanced Accelerator Applications, based in St.-Genis-Pouilly, France, employs more than 550 people at 21 production and research-and-development facilities in 13 countries.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |